283 related articles for article (PubMed ID: 28766214)
21. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
22. Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.
Mamtani A; Nakhlis F; Downs-Canner S; Zabor EC; Morrow M; King TA; Van Zee KJ
Ann Surg Oncol; 2019 Dec; 26(13):4264-4271. PubMed ID: 31440931
[TBL] [Abstract][Full Text] [Related]
23. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
[TBL] [Abstract][Full Text] [Related]
24. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
[TBL] [Abstract][Full Text] [Related]
25. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
[TBL] [Abstract][Full Text] [Related]
26. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
[TBL] [Abstract][Full Text] [Related]
27. Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation.
Punglia RS; Cronin AM; Uno H; Stout NK; Ozanne EM; Greenberg CC; Frank ES; Schrag D
JAMA Oncol; 2017 Jan; 3(1):101-104. PubMed ID: 27442038
[TBL] [Abstract][Full Text] [Related]
28. Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases.
Corradini S; Pazos M; Schönecker S; Reitz D; Niyazi M; Ganswindt U; Schrodi S; Braun M; Pölcher M; Mahner S; Harbeck N; Engel J; Belka C
Radiat Oncol; 2018 Feb; 13(1):25. PubMed ID: 29426355
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M
J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
[TBL] [Abstract][Full Text] [Related]
32. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
[TBL] [Abstract][Full Text] [Related]
33. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
[TBL] [Abstract][Full Text] [Related]
34. Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy.
Muhsen S; Barrio AV; Miller M; Olcese C; Patil S; Morrow M; Van Zee KJ
Ann Surg Oncol; 2017 Dec; 24(13):3888-3895. PubMed ID: 28828599
[TBL] [Abstract][Full Text] [Related]
35. Patterns of care with regard to surgical choice and application of adjuvant radiation therapy for preinvasive and early stage breast cancer in rural Appalachia.
Freeman AB; Huang B; Dragun AE
Am J Clin Oncol; 2012 Aug; 35(4):358-63. PubMed ID: 21422902
[TBL] [Abstract][Full Text] [Related]
36. The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ.
Kane RL; Virnig BA; Shamliyan T; Wang SY; Tuttle TM; Wilt TJ
J Natl Cancer Inst Monogr; 2010; 2010(41):130-3. PubMed ID: 20956816
[TBL] [Abstract][Full Text] [Related]
37. The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study.
Bodilsen A; Bjerre K; Offersen BV; Vahl P; Ejlertsen B; Overgaard J; Christiansen P
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S476-85. PubMed ID: 26178760
[TBL] [Abstract][Full Text] [Related]
38. Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer.
Kruper L; Xu X; Henderson K; Bernstein L
Ann Surg Oncol; 2011 Oct; 18(11):3210-9. PubMed ID: 21863363
[TBL] [Abstract][Full Text] [Related]
39. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
[TBL] [Abstract][Full Text] [Related]
40. Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.
Sprague BL; Vacek PM; Herschorn SD; James TA; Geller BM; Trentham-Dietz A; Stein JL; Weaver DL
Breast Cancer Res Treat; 2019 Feb; 174(1):227-235. PubMed ID: 30448897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
